All the Latest Game Footage and Images from Soul Recursion Soul Recursion is a story focused hack and slash challenging you to explore and uncover the mysteries hidden amongst utopian ruins. Games ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. For its second quarter, Recursion earned $19.2 million in ...

The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. 10 stocks we like better than ...

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. The deal de-risks the company's pipeline by removing uncertainty; however, there's still a long way to go before REV102 is ...

Before market open, Recursion disclosed in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC) that it was taking a series of measures to streamline its operations.

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Recursion Pharmaceuticals (NASDAQ: RXRX) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday. The big gain for the biotech stock came after the U.S. Food and Drug Administration ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence (AI) ...